1. Plasma cell-free DNA promise monitoring and tissue injury assessment of COVID-19
- Author
-
Xin Jin, Yanqun Wang, Jinjin Xu, Yimin Li, Fanjun Cheng, Yuxue Luo, Haibo Zhou, Shanwen Lin, Fei Xiao, Lu Zhang, Yu Lin, Zhaoyong Zhang, Yan Jin, Fang Zheng, Wei Chen, Airu Zhu, Ye Tao, Jingxian Zhao, Tingyou Kuo, Yuming Li, Lingguo Li, Liyan Wen, Rijing Ou, Fang Li, Long Lin, Yanjun Zhang, Jing Sun, Hao Yuan, Zhen Zhuang, Haixi Sun, Zhao Chen, Jie Li, Jianfen Zhuo, Dongsheng Chen, Shengnan Zhang, Yuzhe Sun, Peilan Wei, Jinwei Yuan, Tian Xu, Huanming Yang, Jian Wang, Xun Xu, Nanshan Zhong, Yonghao Xu, Kun Sun, and Jincun Zhao
- Subjects
Genetics ,General Medicine ,Molecular Biology - Abstract
Coronavirus 2019 (COVID-19) is a complex disease that affects billions of people worldwide. Currently, effective etiological treatment of COVID-19 is still lacking; COVID-19 also causes damages to various organs that affects therapeutics and mortality of the patients. Surveillance of the treatment responses and organ injury assessment of COVID-19 patients are of high clinical value. In this study, we investigated the characteristic fragmentation patterns and explored the potential in tissue injury assessment of plasma cell-free DNA in COVID-19 patients. Through recruitment of 37 COVID-19 patients, 32 controls and analysis of 208 blood samples upon diagnosis and during treatment, we report gross abnormalities in cfDNA of COVID-19 patients, including elevated GC content, altered molecule size and end motif patterns. More importantly, such cfDNA fragmentation characteristics reflect patient-specific physiological changes during treatment. Further analysis on cfDNA tissue-of-origin tracing reveals frequent tissue injuries in COVID-19 patients, which is supported by clinical diagnoses. Hence, our work demonstrates and extends the translational merit of cfDNA fragmentation pattern as valuable analyte for effective treatment monitoring, as well as tissue injury assessment in COVID-19.
- Published
- 2023